Targeting RAF1 gene fusions with MEK inhibition in metastatic melanoma.

Autor: Khaddour K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States., Haq R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States., Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States., Manos MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States., Ott PA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States., Hodi FS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States., Insco ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Melanoma Disease Center, Dana-Farber Cancer Institute, Boston, MA 02115, United States.; Harvard Medical School, Boston, MA 02115, United States.

Publikováno v: The oncologist [Oncologist] 2024 Nov 06. Date of Electronic Publication: 2024 Nov 06.

Specific oncogene activation of the cell of origin in mucosal melanoma.

Autor: Babu S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Chen J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Robitschek E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Baron CS; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., McConnell A; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., Wu C; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., Dedeilia A; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA., Sade-Feldman M; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA., Modhurima R; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., Manos MP; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Chen KY; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., Cox AM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Ludwig CG; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., Yang J; Broad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, 02142, USA.; MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, 02139, USA., Kellis M; Broad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, 02142, USA.; MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, 02139, USA., Buchbinder EI; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Hacohen N; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA.; Broad Institute of Massachusetts Institute of Technology (MIT), Cambridge, MA, 02142, USA.; Harvard Medical School (HMS), Boston, MA, USA; Department of Immunology, HMS, Boston, MA, 02115, USA., Boland GM; Massachusetts General Hospital (MGH) Cancer Center, Boston, MA, 02114, USA., Abraham BJ; Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN, 38105, USA., Liu D; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA., Zon LI; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital, Howard Hughes Medical Institute, Boston, MA, 02115, USA., Insco ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02115, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Apr 26. Date of Electronic Publication: 2024 Apr 26.

Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases.

Autor: Wei AZ; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Uriel M; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Porcu A; Department of Medical Oncology Thomas Jefferson University Hospitals, Philadelphia, PA, United States., Manos MP; Dana-Farber Cancer Institute, Boston, MA, United States., Mercurio AC; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Caplan MM; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Hulse L; Department of Medical Oncology Thomas Jefferson University Hospitals, Philadelphia, PA, United States., Seedor RS; Department of Medical Oncology Thomas Jefferson University Hospitals, Philadelphia, PA, United States., Holovatska M; Dana-Farber Cancer Institute, Boston, MA, United States., Francis J; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Khan SA; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., McDonnell DE; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Bogomolny D; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Sato T; Department of Medical Oncology Thomas Jefferson University Hospitals, Philadelphia, PA, United States., Marr BP; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States., Haq R; Dana-Farber Cancer Institute, Boston, MA, United States., Orloff M; Department of Medical Oncology Thomas Jefferson University Hospitals, Philadelphia, PA, United States., Shoushtari A; Memorial Sloan Kettering Cancer Center, New York, NY, United States., Carvajal RD; Division of Hematology & Oncology Columbia University Irving Medical Center, New York, NY, United States.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Sep 08; Vol. 12, pp. 961517. Date of Electronic Publication: 2022 Sep 08 (Print Publication: 2022).

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti-PD-1 Monotherapy.

Autor: Bai X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Hu J; Department of Data Sciences (Division of Biostatistics), Dana-Farber Cancer Institute, Boston, Massachusetts., Betof Warner A; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York., Quach HT; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Cann CG; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Zhang MZ; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Si L; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Tang B; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Cui C; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Yang X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Department of Medical Oncology, Shanxi Bethune Hospital, Shanxi, China., Wei X; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China., Pallan L; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia., Harvey C; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia., Manos MP; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Ouyang O; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Kim MS, Kasumova G, Cohen JV; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Lawrence DP; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Freedman C; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Fadden RM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Rubin KM; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Sharova T; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Frederick DT; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Flaherty KT; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.; Senior authors at each site., Rahma OE; Center for Immune-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Senior authors at each site., Long GV; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.; Senior authors at each site., Menzies AM; Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals, Sydney, Australia.; Senior authors at each site., Guo J; Department of Melanoma and Sarcoma, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China.; Senior authors at each site., Shoushtari AN; Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York.; Senior authors at each site., Johnson DB; Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.; Senior authors at each site., Sullivan RJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts.; Senior authors at each site., Boland GM; Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. gmboland@partners.org.; Senior authors at each site.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Nov 01; Vol. 27 (21), pp. 5993-6000. Date of Electronic Publication: 2021 Aug 10.

Antigen dominance hierarchies shape TCF1 ⁺ progenitor CD8 T cell phenotypes in tumors.

Autor: Burger ML; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Cruz AM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Crossland GE; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Gaglia G; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA., Ritch CC; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA., Blatt SE; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Bhutkar A; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Canner D; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Kienka T; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Tavana SZ; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Barandiaran AL; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Garmilla A; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Schenkel JM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Hillman M; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., de Los Rios Kobara I; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Li A; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Jaeger AM; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Hwang WL; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA., Westcott PMK; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA., Manos MP; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Holovatska MM; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Hodi FS; Melanoma Disease Center, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Center for Immuno-oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02215, USA., Regev A; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA; Genentech, 1 DNA Way, South San Francisco, CA 94080, USA., Santagata S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA 02115, USA; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA; Department of Oncologic Pathology, Dana Farber Cancer Institute, Boston, MA 02215, USA., Jacks T; David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: tjacks@mit.edu.

Publikováno v: Cell [Cell] 2021 Sep 16; Vol. 184 (19), pp. 4996-5014.e26.